Hims & Hers built much of its weight-loss business on compounded GLP-1s during the FDA's semaglutide and tirzepatide shortages. Revenue scaled hard through 2024 and early 2025, then ran into the post-shortage rules.
What's happened since: the Outsourcing Facilities Association litigation, the April 30, 2026 FDA proposal to exclude branded GLP-1s from the 503B bulks list, the University of Colorado secret-shopper study showing telehealth peptide programs that kept selling compounded GLP-1s after the shortage cleared, and Hims & Hers' own pivot toward additive formulations and broader peptide therapy programs (sermorelin, peptide stacking). The August 10, 2026 Q2 2026 print delivered revenue of $753.2M (+38% YoY, beating consensus of $698.9M), subscribers of approximately 2.9M (+19% YoY), US revenue of $621.8M (+16%), and international revenue of $131.4M (+17-fold YoY via the Eucalyptus acquisition that closed in June). Full-year 2026 guidance was raised to $3.1-3.3B revenue and $275-325M Adjusted EBITDA. The catch: gross margin compressed to 64% from 76% year-ago on the compounded-to-branded GLP-1 pivot, and Q2 net loss reached $86.3M versus $42.5M net income in Q2 2025.
July 23, 2026 was the biggest single-day peptide catalyst for the stock. Shares surged 10-13% intraday after the FDA PCAC voted 8-6 with 1 abstention to recommend BPC-157 for the 503A bulks list, followed by the identical 8-6-1 vote for KPV. Chief Medical Officer Dr. Anant Vinjamoori's public-comment testimony reportedly moved undecided panelists: he described a colleague's photograph of a bodega in Queens selling peptides and argued that a no vote would push the trade deeper into an unregulated gray market rather than end demand. Six days later, on July 29, 2026, the FTC filed suit alleging the company shared consumer sensitive health information with Meta and Snap through embedded website tracking, and separately alleging unauthorized billing charges; Los Angeles County and Utah joined as co-plaintiffs, HIMS dropped 10% on the announcement, and Bank of America cut its price target to $30 from $37. Stories here cover the compounding strategy, regulatory exposure, and the quarterly numbers. See [[hims-and-hers]] and [[telehealth]] for adjacent threads.
Hims & Hers Health (NYSE: HIMS) shares fell approximately 6% after hours Monday and extended the decline into Tuesday August 11, 2026 trading despite Q2 2026 revenue of $753.2 million (+38% year-over-year, beating $698.9 million consensus) and Q3 guidance of $890 million at the midpoint (+12.4% above analyst expectations). The GAAP loss of $0.37 per share ran well below analyst estimates, and gross margin compression to 64% (from 76% year-ago) hit its fourth consecutive quarter of decline. Q2 net loss reached $86.3 million versus $42.5 million net income in Q2 2025. The compounded-to-branded GLP-1 pivot through the Novo Nordisk (Wegovy, Ozempic) and Eli Lilly (Zepbound, Mounjaro) commercial partnerships since Q1 2026 continues to drag unit economics. Full-year 2026 guidance was raised to $3.1-3.3 billion revenue and $275-325 million Adjusted EBITDA. The market appears to be pricing the compounded-to-branded pivot as a durable margin drag rather than a transitory transition; the July 29 FTC lawsuit alleging consumer health data sharing with Meta and Snap plus unauthorized billing charges remains a substantive overhang. Chief Medical Officer Dr. Anant Vinjamoori's July 23 PCAC harm-reduction testimony framing continues to shape the peptide-strategy narrative for the stock.
Hims & Hers Health (NYSE: HIMS) reported Q2 2026 earnings after market close Monday August 10, 2026. Revenue reached $753.2 million (+38% year-over-year), beating consensus of $698.9 million. US revenue was $621.8 million (+16% YoY); international revenue climbed to $131.4 million (+17-fold year-over-year) aided by the completion of the Eucalyptus acquisition in June 2026. Subscribers grew to approximately 2.9 million (+19% YoY). The company raised full-year 2026 guidance to $3.1-3.3 billion in revenue and $275-325 million in Adjusted EBITDA. Net loss was $86.3 million versus $42.5 million net income in Q2 2025 as gross margin compressed to 64% from 76% year-ago; the compression reflects the strategic pivot from compounded GLP-1s (higher margin) to branded GLP-1 supply (lower margin) through Novo Nordisk (Wegovy, Ozempic) and Eli Lilly (Zepbound, Mounjaro) commercial partnerships since Q1 2026. The FTC lawsuit filed July 29 alleging the company shared consumer sensitive health information with Meta Platforms and Snap Inc. through embedded tracking technologies and separately alleging unauthorized billing charges (with Los Angeles County and Utah as co-plaintiffs) remains a substantive overhang. Chief Medical Officer Dr. Anant Vinjamoori's July 23 PCAC harm-reduction testimony framing continues to shape the post-PCAC peptide-strategy narrative.
The post-PCAC telehealth peptide competitive landscape continues to shape investor attention. Hims & Hers Health (NYSE: HIMS) Q2 2026 revenue of $753.2 million (+38% YoY) reported Monday August 10 after market close positions Hims as the largest US telehealth peptide-strategy sponsor. LifeMD (NASDAQ: LFMD) has approximately 310,000 active telehealth subscribers per recent investor materials, with 2025 revenue guided at $265-275 million. Ro and Henry Meds round out the large-player telehealth set. Key institutional commenters supporting the July 23-24, 2026 FDA Pharmacy Compounding Advisory Committee (PCAC) 6-of-7 vote recommendation included the Alliance for Pharmacy Compounding, Empower Pharmacy, American Institute for Compounded Therapeutics, Texas Pharmacy Association, real-world data platform Peptide AI, and the American Academy of Peptide Medicine. The July 23-24 vote recommendation (BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon approved 6 of 7; Emideltide/DSIP rejected) sets up the prospective legal compounding channel once FDA rulemaking completes (typically 12-24 months per PCAC-recommended substance). Enforcement context: the FDA issued 40+ warning letters and 100+ cease-and-desist notices to compounders and telehealth companies in 2024-2025 (the single largest enforcement action in compounding-pharmacy regulation history), and by March 2026 the FDA had sent warning letters to 30 additional telehealth companies with total enforcement actions exceeding 125 warning and untitled letters. The February 2027 PCAC second-peptide meeting (LL-37, GHK-Cu, dihexa acetate, melanotan II, PEG-MGF) will further shape the compounding landscape.
Hims & Hers Health (NYSE: HIMS) reports Q2 2026 earnings Monday August 10, 2026 after market close under the shadow of the July 29, 2026 Federal Trade Commission (FTC) lawsuit. FTC allegations: the company shared consumer sensitive health information with Meta Platforms, Snap Inc., and other online advertising platforms through embedded website tracking technologies (pixel-based cookie/session tracking) without meeting informed-consent requirements; and separately, that the company charged some patients for prescriptions they did not order. Los Angeles County and Utah joined the FTC as co-plaintiffs, expanding both the geographic exposure and the potential remedy set. HIMS shares dropped 10% on the July 29 announcement. Bank of America analyst Allen Lutz reiterated Hold and cut the price target to $30 from $37 on FTC-lawsuit uncertainty, characterizing the outcome as a small-fee base case. Wall Street consensus for Q2 2026: $698.9 million revenue (+28.3% year-over-year) and -$0.05 diluted EPS loss versus the +$0.17 year-ago quarter. Options traders are pricing an approximate 14.5% post-earnings move in either direction. Analyst focus areas: peptide-compounding revenue trajectory (Leerink pegs $440M peptide sales for full-year 2026), FTC lawsuit financial and operational impact, and branded GLP-1 partnership contribution since Q1 2026.
Hims & Hers Health (NYSE: HIMS) reports Q2 2026 earnings Monday August 10, 2026 after market close under the shadow of a Federal Trade Commission (FTC) lawsuit alleging the company shared consumer sensitive health information with third-party advertising platforms without meeting HIPAA-compatible informed-consent requirements. Wall Street consensus: $698.9 million revenue (+28.3% year-over-year) and approximately -$0.05 diluted EPS loss versus +$0.17 EPS in the year-ago quarter. Bank of America analyst Allen Lutz cut the HIMS price target to $30 from $37 (maintaining Hold), citing FTC-lawsuit uncertainty with a small-fee base-case framing. Options traders are pricing an approximate 14.5% post-earnings move in either direction. Analyst focus areas beyond top-line numbers: post-PCAC peptide-compounding revenue trajectory (Leerink estimates $440 million peptide sales in 2026 representing 15% of the projected revenue midpoint); FTC lawsuit financial and operational impact; branded GLP-1 (Wegovy/Ozempic/Zepbound/Mounjaro) commercial partnership contribution since Q1 2026; and Chief Medical Officer Dr. Anant Vinjamoori's July 23 PCAC harm-reduction testimony framing for the Hims peptide strategy narrative. Truist analysts have cautioned that substantial peptide revenue is unlikely before 2028 even with the PCAC advisory support given the 12-24 month FDA rulemaking timeline.
Hims & Hers Health (NYSE: HIMS) reports Q2 2026 earnings Monday August 10, 2026 after market close, with a live conference call scheduled for 5:00 PM ET. Koyfin consensus estimates: revenue of $730.12 million (+20% year-over-year), $47.26 million EBITDA (+7% YoY), and $0.11 adjusted diluted EPS. Analyst focus areas beyond the top-line numbers: the peptide-compounding revenue trajectory following the July 23-24 FDA Pharmacy Compounding Advisory Committee (PCAC) 6-of-7 vote recommending BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon for the Section 503A Bulks List (DSIP was rejected); the branded GLP-1 supply migration through the Novo Nordisk Wegovy/Ozempic and Eli Lilly Zepbound/Mounjaro commercial partnerships since Q1 2026; and management commentary on the FDA rulemaking timeline (typically 12-24 months per PCAC-recommended substance) that gates when the July 23-24 PCAC recommendation actually translates into new compounded-peptide revenue lines. Leerink analysts estimate Hims peptide sales at approximately $440 million in 2026, representing roughly 15% of the projected 2026 revenue midpoint; Truist analysts have cautioned that substantial peptide revenue is unlikely before 2028 even with the PCAC advisory support. Chief Medical Officer Dr. Anant Vinjamoori's July 23 PCAC public-comment testimony (which reportedly moved several undecided panelists on the harm-reduction argument for legal 503A compounded peptides) added a public-facing dimension to the Hims peptide strategy that will likely be referenced on the earnings call.
Post-PCAC analyst coverage of Hims & Hers Health (NYSE: HIMS) split on the July 23-24 Pharmacy Compounding Advisory Committee (PCAC) 6-of-7 outcome. BofA Securities raised its price target to $36 on the peptide-compounding opportunity, and Canaccord Genuity raised to $40, both citing the July 23-24 PCAC vote and the Hims & Hers acquired California peptide manufacturing facility. Analysts estimate the four Day-1 recommended peptides (BPC-157, KPV, TB-500, MOTS-c) could generate approximately $440 million in Hims & Hers sales by 2027 if the FDA follows through with 503A rulemaking. Truist Securities held at $23 citing the 6-18 month FDA rulemaking timeline and continued uninsured-patient exposure. Barclays sits at $39 (Novo Nordisk partnership thesis). The peptide catalyst lift is tempered by the advisory-vote nature of the PCAC outcome: compounding pharmacies still cannot legally prepare BPC-157, KPV, TB-500, MOTS-c, Semax, or Epitalon under Section 503A today because none of the six substances are on the 503A Bulks List. FDA rulemaking to add each substance takes 6-18 months from the date the agency decides to act. Hims shares closed near $28.50 last week after briefly rallying above $35 on the initial vote outcome.
Bloomberg Businessweek published a long-form feature this week titled 'Peptides Fuel a Multibillion-Dollar Startup Race' covering the peptide industry's post-PCAC-vote investor landscape. The story frames the July 23-24 PCAC recommendation of 6 of 7 peptides for the Section 503A Bulks List as the trigger for a legalization gold rush and profiles the compounding-pharmacy, telehealth, manufacturing, and startup ecosystem positioning to capture what analysts describe as the multibillion-dollar non-GLP-1 peptide market. The feature draws on the analyst framing established earlier in 2026 (Jonah Lupton's projection that Hims & Hers could generate $10-19 billion in annual peptide-related revenue by 2030 if the company captures 4-5% of combined GLP-1 and non-GLP-1 peptide markets) and profiles the venture-capital financing wave, including the General Bio $7.4 million seed round for oral peptide platform work (Axios Pro exclusive July 20), the MindRank $52 million Series B for AI-driven peptide discovery (July 10 digest coverage), and the Samsung Biologics $1.8 billion all-cash tender offer for PolyPeptide (July 19-20 digest coverage). The Bloomberg piece anchors the investment thesis on the 6-of-7 PCAC recommendation while noting that FDA rulemaking to actually add BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon to the 503A list takes 6-18 months per substance from the date the agency decides to act.
Hims & Hers Health (NYSE: HIMS) shares surged 10-13% intraday on Thursday July 23, 2026 following the FDA Pharmacy Compounding Advisory Committee (PCAC) 8-6 votes in favor of adding BPC-157 and KPV to the Section 503A Bulks List. The stock reaction reflected investor recognition that Hims & Hers is one of the largest telehealth commercial channels positioned to sell legally compounded peptides through licensed 503A pharmacies if the FDA follows the advisory recommendation and completes rulemaking. Hims Chief Medical Officer Dr. Anant Vinjamoori's public-comment testimony was reportedly influential in the panel outcome. Vinjamoori shared the anecdote that a colleague had recently sent him a photograph of a bodega in Queens selling peptides, then argued: 'A no vote would not end those distribution channels or use. It would instead move it deeper into a market with no production or sourcing standards, no physician, no monitoring, and no record.' Vinjamoori also acknowledged the 'relatively sparse clinical evidence for these peptides' before making the harm-reduction argument. Hims stands to benefit commercially: the company has built peptide capabilities including a California manufacturing facility acquired in 2025.
The FDA Pharmacy Compounding Advisory Committee (PCAC) written-comment docket FDA-2025-N-6895 closes at 11:59 PM ET on Wednesday July 22, 2026. Approximately 1,860 public comments have been filed on the seven-peptide review, spanning docket comments from institutional commenters supporting inclusion (Hims & Hers Health among them) and opposing inclusion (PhRMA, Partnership for Safe Medicines, American Pharmacists Association, Public Citizen, Institute for Safe Medication Practices, UC Davis's Paul Knoepfler). Hims Chief Medical Officer Dr. Anant Vinjamoori confirmed Hims will testify at Thursday's July 23 hearing at FDA's White Oak Campus in Silver Spring, Maryland. In pre-hearing remarks, Dr. Vinjamoori said medical providers should be honest about 'the relatively sparse clinical evidence for these peptides' but noted that Hims plans to offer the peptides if the FDA reclassifies them. He also cited nearly a decade of accumulated experience across 'thousands of physicians, close to millions of patients' that in his view supports the peptides' health benefits. FDA career-staff briefing documents recommend against adding any of the seven peptides to the 503A Bulks List. PCAC recommendations are advisory; FDA rulemaking (typically 6-18 months) is required before compounding pharmacies can act on any positive committee recommendation.
Fortune published Monday July 20, 2026 a feature framing the FDA Pharmacy Compounding Advisory Committee's July 23-24 peptide vote as a potential commercial inflection point for the telehealth industry. The article positions Hims & Hers (NYSE: HIMS), Ro, LifeMD (NASDAQ: LFMD), and other GLP-1 telehealth platforms as the natural commercial channels for legal peptide compounding if any of the seven peptides win 503A bulks-list eligibility. The commercial thesis: compounded GLP-1 volume has been the primary telehealth growth driver over 2024-2026, but the April 2025 FDA determination that semaglutide and tirzepatide shortages had resolved (and the April 30, 2026 proposed permanent 503B exclusion) closed the compounding channel for weight-loss demand; a favorable PCAC recommendation followed by FDA rulemaking would open a fresh compoundable-substance category (BPC-157, TB-500, KPV, MOTS-c, and others) that telehealth companies could sell into legally through licensed 503A pharmacies. The Fortune feature ran the same day as the STAT News investigation of LifeMD alleging former-employee patient-safety concerns; the two stories together frame the telehealth channel as simultaneously commercially opportunistic and clinically under scrutiny.
Analyst dispersion around Hims & Hers Health (NYSE: HIMS) widened this week following the FDA career-staff briefing documents released June 29-30 concluding all seven PCAC peptides have insufficient evidence for 503A bulks-list inclusion. The four fresh price targets span nearly two-to-one: Truist Securities reiterated a Hold rating with a $23 price target, citing near-term-performance strength tempered by uncertainty around peptide-compounding regulation. BofA Securities raised its price target to $36 from $25 while maintaining Neutral, noting the FDA update is negative for the company's peptide-optionality narrative but not the core weight-loss business. Barclays' Glen Santangelo raised to $39 from $29 while maintaining Overweight, crediting improvements from the renewed Novo Nordisk partnership. Canaccord's Maria Ripps raised to $40 from $32 while maintaining Buy, citing the company's transition from compounded to branded weight-loss drugs. The 74% spread from lowest to highest target reflects analyst disagreement about how much of the Hims growth story now runs through peptide optionality versus branded-GLP-1 rails.
Analyst coverage of Hims & Hers (NYSE: HIMS) ahead of the July 23-24 PCAC meeting consolidated through the weekend with two distinct framings. Leerink Partners' Michael Cherny called the PCAC vote a 'modest binary event,' acknowledging that an affirmative outcome on BPC-157, KPV, TB-500, MOTS-c, Emideltide/DSIP, Semax, or Epitalon would open real upside starting FY2027 and beyond (peptides as a large new product category for the company's owned California compounding facility), while flagging the procedural caveat that PCAC votes have a mixed record and the FDA does not always follow committee recommendations. Canaccord Genuity reiterated a 'Buy' rating on HIMS with a $32 price target framing peptides as part of the company's long-term preventive-health, longevity, and wellness portfolio expansion. The two analyst views sit alongside Barclays' June 17 PT raise to $39 (Overweight, weight-loss-momentum thesis). HIMS stock entered Monday June 29 up roughly 29.79% in June despite a 1.62% intraday decline, with the convergence of analyst price targets and the binary July 23-24 PCAC catalyst positioning the company as one of the most-watched names in the obesity-and-longevity telehealth space heading into Q3 2026.
Hims & Hers Health (NYSE: HIMS) is up roughly 25% in June 2026 on multiple converging investor signals heading into the final week of the month. Novo Nordisk leadership called Hims one of its most 'voluminous' telehealth partners on a recent earnings call, validating the March 2026 branded-supply pact that ended the prior compounded-GLP-1 litigation. Leerink reiterated its Market Perform rating ahead of the July 23-24 FDA Pharmacy Compounding Advisory Committee (PCAC) meeting, framing peptides as the company's next major product category and a key 2027+ growth driver. Barclays raised its price target to $39 from $29 on June 17 with an Overweight rating. CEO Andrew Dudum confirmed Oura Ring integration is 'coming soon,' adding wearable connectivity to the platform. The Hims GLP-1 subscription stack now runs $39 for the first month and $149 monthly thereafter (excluding medication costs), with branded Novo Wegovy injections and pills available alongside the company's owned California compounding-pharmacy capacity for the post-PCAC peptide expansion. The convergence of investor signals (analyst PT raises, Novo validation, PCAC catalyst, wearable integration) makes HIMS one of the most-watched names in the obesity-and-longevity telehealth space heading into Q3 2026.
Hims & Hers Health (NYSE: HIMS) broke above $30 on June 22, 2026 for the first time since April, finishing the month +36% — its best month since March — on rising investor confidence in the company's peptide platform ahead of the July 23-24 FDA Pharmacy Compounding Advisory Committee (PCAC) meeting. Leerink called the PCAC meeting a key catalyst, framing peptides as Hims' next major product category supporting growth beyond 2027. FirstWave Fund CEO Jonah Lupton projected Hims could generate $10-19 billion in annual peptide-related revenue by 2030 if it captures 4-5% of the combined GLP-1 and non-GLP-1 peptide markets. Hims acquired a California peptide manufacturing facility in 2025 and added in-house lab testing capabilities. CEO Andrew Dudum confirmed Oura Ring integration is 'coming soon,' signaling deeper wearable connectivity. The June 22-23 stock move reflects the broader market consensus that PCAC will reclassify the seven peptides under review (BPC-157, KPV, TB-500, MOTS-C, Emideltide, Semax, Epitalon) and open compounding-pharmacy supply channels.
Hims & Hers Health announced May 18 the pricing of an upsized $350M aggregate principal amount of 0.00% convertible senior notes due 2032, with settlement May 21. Initial conversion rate is 33.8590 shares of Class A common stock per $1,000 principal — a conversion price of approximately $29.53 per share, representing a 32.5% premium over the $22.29 close on May 18. The capped call cap price was set at approximately $50.15 per share (125% premium). Initial purchasers granted an option to buy up to an additional $52.5M in notes within 13 days. Proceeds support international expansion strategy and the proposed acquisition of Eucalyptus (Australian-based digital health platform with peptide and weight-management presence in Australia, UK, and Germany) expected to close mid-2026. The convertible structure preserves cash for the international rollout while the Novo Nordisk branded distribution partnership scales US Wegovy supply.
Hims & Hers disclosed in post-Q1 commentary picked up by Stocktwits and Yahoo Finance that the company has fulfilled approximately 125,000 Wegovy shipments since the Novo Nordisk branded-distribution partnership activated on March 26, 2026 — roughly 21,000 per week in operational terms. The volume signals materially stronger Wegovy uptake through the Hims platform than the Q1 print's $608M revenue figure suggested, with most of the contribution landing in Q2 books. Subscriber count held at 2.6M (+9% YoY), monthly average revenue per subscriber dropped to $80 from $85 on the product-mix shift, and full-year guidance was raised to $2.8-3.0B revenue. Deutsche Bank's George Hill trimmed his target to $25 from $28 (Hold). The 'Netflix of healthcare' framing from major investor Cathie Wood persists despite the post-print drop; HIMS shares partially recovered to $29.14 in early-week trading.
Hims & Hers shares fell ~13% after the May 11 Q1 print as $608.1M revenue missed the $616.9M consensus and gross margin compressed from 73% to 65% on the compounded-semaglutide wind-down. JPMorgan trimmed its price target to $33 from $35 (Overweight reaffirmed); Canaccord raised to $32 from $30 (Buy). The Motley Fool published a 'Is HIMS Stock a Buy After Latest Dip?' analysis on May 14 framing the post-print decline as a buying opportunity, citing the 9% subscriber growth to 2.6M, the raised full-year guide ($2.8-3.0B revenue, $275-350M Adjusted EBITDA), and the structural lift from the Novo Nordisk branded-Wegovy distribution deal landing in Q2 books. The split between bullish and cautious analyst takes captures the central tension: high-growth telehealth navigating a margin-dilutive product transition.